US-based therapeutic devices developer Aethlon Medical has announced that its Hemopurifier device has been named as one of the 25 best inventions of 2014 by Time Magazine.
The first-class bio-filtration device Hemopurifier eliminates viruses and immunosuppressive proteins from the circulatory system of infected individuals.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Hemopurifier targets the rapid elimination of circulating viruses and tumour-secreted exosomes that promote cancer progression.
The device was used in the treatment of Ebola, human immunodeficiency virus (HIV) and Hepatitis C.
The Hemopurifier therapy was recently successful in treating an Ebola patient with multiple organ failure.
In September, the company received independent internal review board (IRB) approval to initiate human clinical trials of Hemopurifier therapy at DaVita Med Center Dialysis in Houston, Texas, US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe US Food and Drug Administration (FDA) previously approved an investigational device exemption (IDE), allowing the start of Hemopurifier feasibility studies in the US.
As a result of the independent IRB approval, the company is now permitted to start the IDE approved trial.
Patients who meet the inclusion / exclusion criteria of the trial are expected to be enrolled in the next few weeks.
Image: Aethlon Hemopurifier. Photo: courtesy of Aethlon Medical Inc.
